Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

90.61 +0.75 (+0.83%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

74 75 Next >

Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst ↗

September 28, 2023

Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.

Via Benzinga

Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs ↗

September 28, 2023

AstraZeneca Plc (NASDAQ: AZN), Bristol Myers Squibb & Co (NYSE: BMY), and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiation

Via Benzinga

AstraZeneca Unusual Options Activity For September 28 ↗

September 28, 2023

Via Benzinga

Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges ↗

September 27, 2023

Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY

Via Benzinga

Biden's Urgent Action Against Antibiotic-Resistant Bacteria - Allocates $100M to Battle Deadly Superbugs ↗

September 27, 2023

U.S. President Joe Biden is set to unveil a $100 million research initiative to tackle the growing threat of drug-resistant bacteria. More than a million people worldwide succumb to infections caused...

Via Benzinga

Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories ↗

September 27, 2023

Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO

Via Benzinga

Topics Artificial Intelligence

Weight Loss Drugs Like Wegovy Could Have Linked Anesthesia Complications, European Medicines Agency To Investigate ↗

September 27, 2023

The European Medicines Agency (EMA) is set to address concerns related to patients taking drugs such as Novo Nordisk A/S's (NYSE

Via Benzinga

Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder ↗

September 26, 2023

IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder.

Via Investor's Business Daily

Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant ↗

September 26, 2023

Read the latest report on NanoViricides here

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023 ↗

September 25, 2023

Via Benzinga

Baidu To Rally Over 29%? Here Are 10 Other Analyst Forecasts For Monday ↗

September 25, 2023

Goldman Sachs increased the price target for Constellation Brands, Inc. (NYSE: STZ) from $275 to $305. Goldman Sachs analyst Bonnie Herzog maintained a Buy rating. Constellation shares fell 0.8% to...

Via Benzinga

Argenx's 28% Surge & Promising Product Propel Investor Confidence

September 25, 2023

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

Via MarketBeat

3 Magnificent Growth Stocks to Buy Right Now ↗

September 24, 2023

If you're looking for growth, these stocks could be just the ticket.

Via The Motley Fool

AstraZeneca Surges To 50-Day Line After Breast Cancer Drug Tops Chemo ↗

September 22, 2023

The companies are still testing to see if their drug has a benefit on overall survival.

Via Investor's Business Daily

Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting ↗

September 22, 2023

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC:

Via Benzinga

Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial

September 22, 2023

From AstraZeneca

Via Business Wire

On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope

September 20, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 20, 2023 – USA News Group – Earlier this year, the US White House requested over $2.8 billion in funding from Congress...

Via FinancialNewsMedia

Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers – Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment ↗

September 15, 2023

One in eight women will be diagnosed with breast cancer during

Via Benzinga

AstraZeneca advances UK clean heat and energy efficiencies with £100m commitment

September 14, 2023

From AstraZeneca

Via Business Wire

AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst ↗

September 11, 2023

On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients

Via Benzinga

FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)

September 11, 2023

From AstraZeneca

Via Business Wire

Qualcomm-Apple's Chip Supply Agreement, Alleged Report About AstraZeneca CEO Sir Pascal Soriot's Intention To Step Down, Apple & Google Face Off in Antitrust Showdown: Today's Top Stories ↗

September 11, 2023

Benzinga Qualcomm Announces Chip Supply Agreement With Apple

Via Benzinga

What's Going On With AstraZeneca Stock Today? ↗

September 11, 2023

Shares in European pharmaceutical giant AstraZeneca Plc (NASDAQ: AZN) are down amid speculations swirling around the potential departure of AstraZeneca's Chief Executive, Pascal Soriot.

Via Benzinga

AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials ↗

September 11, 2023

Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) and AstraZeneca plc (NASDAQ: AZN) released initial results from the TROPION-Lung04 phase 1b tria

Via Benzinga

TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial

September 11, 2023

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial

September 11, 2023

From AstraZeneca

Via Business Wire

4 Top-Tier Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

September 09, 2023

Deals can still be found with the Nasdaq Composite roughly 14% below its record-closing high.

Via The Motley Fool

Topics Stocks

Johnson & Johnson Cancer Drug Rybrevant Shows Improvement In Broader Lung Cancer Population ↗

September 06, 2023

Janssen, a unit of Johnson & Johnson (NYSE: JNJ),

Via Benzinga

FDA Seeks Further Safeguards for AstraZeneca's Ultomiris Therapy, But Efficacy Not in Question ↗

September 06, 2023

The FDA has issued a complete response letter (CRL) regarding AstraZeneca Plc's (NASDAQ:

Via Benzinga

3 Forever Stocks to Buy With $100 ↗

September 05, 2023

With $100 or less, you can buy at least one share of one of these top stocks.

Via The Motley Fool

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.